Skip to main content
[Preprint]. 2023 Apr 13:2023.04.12.536558. [Version 1] doi: 10.1101/2023.04.12.536558

Figure 4. FGF-21 increases in a VEGF-dependent manner in murine models of kidney cancer.

Figure 4.

(A) Plasma FGF-21 concentrations in a mouse model of renal adenoma (n=5 per group). (B)-(C) Plasma FGF-21 concentrations in mouse models of renal cell carcinoma (n=5 per group, with the exception of week 3 in kidney Renca tumor-bearing mice, in which n=4 due to the death of one of the mice). (D) FGF-21 concentrations in healthy mice treated acutely with recombinant VEGF (n=5). (E) Survival probability in RCC patients with low and high (lowest and highest 25th percentile) Slc2a1 (GLUT1) expression43 (n=219 per group). (F) Survival probability in RCC patients with low and high (lowest and highest 25th percentile) expression of both Vegfa (VEGF) and Slc2a1 (GLUT1) (n=224 per group). In all panels, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.